CN1514727A - 在前列腺癌患者中与健康相关的生活质量和与健康相关的质量-调节时间对疾病的进展的有利调节 - Google Patents

在前列腺癌患者中与健康相关的生活质量和与健康相关的质量-调节时间对疾病的进展的有利调节 Download PDF

Info

Publication number
CN1514727A
CN1514727A CNA028116720A CN02811672A CN1514727A CN 1514727 A CN1514727 A CN 1514727A CN A028116720 A CNA028116720 A CN A028116720A CN 02811672 A CN02811672 A CN 02811672A CN 1514727 A CN1514727 A CN 1514727A
Authority
CN
China
Prior art keywords
trans
pyrrolidine
benzodioxol
methyl
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028116720A
Other languages
English (en)
Chinese (zh)
Inventor
A
A·辛
R·J·帕利
T·阿斯拉夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/832,752 external-priority patent/US20030022811A1/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CN1514727A publication Critical patent/CN1514727A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA028116720A 2001-04-11 2002-04-11 在前列腺癌患者中与健康相关的生活质量和与健康相关的质量-调节时间对疾病的进展的有利调节 Pending CN1514727A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/832,752 US20030022811A1 (en) 2001-04-11 2001-04-11 Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
US09/832,752 2001-04-11
US11848602A 2002-04-08 2002-04-08
US10/118,486 2002-04-08

Publications (1)

Publication Number Publication Date
CN1514727A true CN1514727A (zh) 2004-07-21

Family

ID=26816420

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028116720A Pending CN1514727A (zh) 2001-04-11 2002-04-11 在前列腺癌患者中与健康相关的生活质量和与健康相关的质量-调节时间对疾病的进展的有利调节

Country Status (10)

Country Link
EP (1) EP1379238A1 (enExample)
JP (1) JP2005503339A (enExample)
CN (1) CN1514727A (enExample)
AR (1) AR033465A1 (enExample)
BR (1) BR0205970A (enExample)
CA (1) CA2442591A1 (enExample)
IL (1) IL158071A0 (enExample)
MX (1) MXPA03009277A (enExample)
PE (1) PE20021032A1 (enExample)
WO (1) WO2002085351A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023011596A1 (zh) * 2021-08-05 2023-02-09 中国药科大学 酰胺类化合物及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
WO2004100991A1 (en) * 2003-05-15 2004-11-25 Universite Catholique De Louvain Use of endothelin-1 antagonists for improving cancer therapy
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
JP2009537535A (ja) * 2006-05-15 2009-10-29 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド エンドセリンアンタゴニストの投与を含む睡眠時無呼吸を治療するための方法および組成物
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200101234T2 (tr) * 1997-08-04 2002-06-21 Abbott Laboratories Endotelin antagonistleri.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023011596A1 (zh) * 2021-08-05 2023-02-09 中国药科大学 酰胺类化合物及其应用

Also Published As

Publication number Publication date
MXPA03009277A (es) 2004-03-10
AR033465A1 (es) 2003-12-17
EP1379238A1 (en) 2004-01-14
BR0205970A (pt) 2003-09-30
JP2005503339A (ja) 2005-02-03
IL158071A0 (en) 2004-03-28
PE20021032A1 (es) 2002-11-12
CA2442591A1 (en) 2002-10-31
WO2002085351A1 (en) 2002-10-31

Similar Documents

Publication Publication Date Title
CN1177833C (zh) 取代的间二氮杂萘衍生物
CN1196484C (zh) 联合用作抗癌剂的药物组合物
CN1308535A (zh) 供治疗关节病的法呢基(Farnesyl)蛋白质转移酶抑制剂
CN1735416A (zh) 治疗剂组合
CN1520290A (zh) 含铜胺氧化酶的碳环肼基抑制剂
CN1976704A (zh) 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途
JP6528779B2 (ja) びまん性大細胞型ｂ細胞リンパ腫の予防および／または治療剤
CN1589264A (zh) 用于治疗恶性肿瘤的方法
CN1039491C (zh) 四氢咔唑化合物及其制备方法和应用
CN1646168A (zh) 使用抗惊厥剂衍生物和抗偏头痛药物治疗偏头痛的联合治疗
CN1630534A (zh) 治疗过度增殖疾病的方法和组合物
CN101065127A (zh) 包含埃博霉素和蛋白酪氨酸激酶抑制剂的组合产品及其药物用途
CN1703207A (zh) GSK－3β抑制剂在制备增加骨生成的药物中的应用
CN1512879A (zh) 新的芳氨基丙烷类似物及其用于治疗青光眼的用途
CN1956714A (zh) 用于治疗下泌尿道病症的α－氨基酰胺衍生物
CN1514727A (zh) 在前列腺癌患者中与健康相关的生活质量和与健康相关的质量-调节时间对疾病的进展的有利调节
CN1121389C (zh) 细胞增生抑制剂氰基胍
CN1933832A (zh) 离子通道调节剂
US20030092757A1 (en) Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
CN1913892A (zh) 药物组合物及联合药物
CN1111988A (zh) 取代的芳族甾类化合物控制生育力的用途及其药物组合物
CN1652844A (zh) 用于癌症治疗的cdk抑制剂和5－fu的联合
CN1206991C (zh) 含有盐酸西替利嗪和盐酸伪麻黄碱的制剂及其制备方法
CN1968686A (zh) 脒腙盐、组合物、制备方法和使用方法
CN1324011C (zh) 用于治疗疼痛的氮杂－螺环化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned